The Hyperlipidemia Drugs Market was valued at US$ 24.90 Billion in 2025 and is projected to reach US$ 31.09 Billion by 2034, registering a CAGR of 2.5% during 2026–2034. The market is expanding as healthcare providers focus on reducing elevated cholesterol and associated cardiovascular risks among patients with hyperlipidemia. Growth is supported by the rising...